Switzerland-based Novartis has one of the strongest and broadest portfolios of varied drugs that has enabled it to maintain its dominant position as a top pharma company over the years. It continues to build depth in core therapeutic areas like cardiovascular, renal and metabolic, immunology, neuroscience and oncology in geographies like the United States, China, Germany and Japan. Novartis’ efforts to strengthen its wide portfolio by developing breakthrough treatments have made it even more formidable in this space. Cosentyx, Entresto, Kesimpta, Pluvicto, Scemblix, Zolgensma, Kisqali and Leqvio should fuel growth through 2030 and beyond.

Given the evolving and competitive nature of the pharma business, Novartis has constantly taken steps to reshape its business with prudent acquisitions and strategic divestitures. In January 2015, Novartis divested its Animal Health division to Lilly for approximately $5.4 billion. In July 2015, the company divested its influenza vaccines business to CSL Limited for $275 million. Novartis has also acquired The Medicines Company, adding Leqvio — a transformative cholesterol-lowering therapy — to its portfolio. Novartis sold its investment in Roche for $20.7 billion in 2021.

In July 2023, Novartis acquired DTx Pharma Inc., a U.S.-based, preclinical-stage biotechnology company focused on leveraging its proprietary FALCON platform to develop siRNA therapies for neuroscience indications. In August 2023, Novartis acquired Chinook Therapeutics, Inc., a U.S.-based, clinical-stage biopharmaceutical company with two late-stage medicines in development for rare, severe chronic kidney diseases.

In 2023, Novartis transformed into a pure-play innovative medicines business, with the successful spin-off of its generic business Sandoz. Consequently, Novartis now operates as a single global operating segment.

Sales in 2023 totaled $45.4 billion, up 8% year over year.